凝血酶原複合濃縮物市場機會、成長動力、產業趨勢分析與預測 2024 - 2032

Prothrombin Complex Concentrate Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032

出版日期: 2024年10月22日 | 出版商:

Global Market Insights Inc. | 英文 131 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023 年，全球凝血酶原複合濃縮物市場價值為21 億美元，預計2024 年至2032 年複合年成長率為9.4%。不斷增加推動的。凝血障礙的激增極大地促進了全球 PCC 市場的擴張。隨著出血性疾病和後天性凝血障礙等疾病變得越來越常見，對 PCC 等有效、快速治療方案的需求也越來越大。維生素 K 缺乏、肝臟疾病和抗凝血藥物的廣泛使用等因素進一步強調了 PCC 的重要性，特別是在需要快速介入的緊急情況下。

市場依產品類型分為4因素PCC和3因素PCC。 2023 年，四因子 PCC 細分市場引領市場，創造約 12 億美元。該產品由於起效快且在治療各種病症方面具有多功能性（包括逆轉直介面服抗凝血劑），因此通常在重症監護環境中成為首選。各衛生組織臨床指引對四因素 PCC 的大力認可鞏固了其在凝血相關治療領域的地位，進一步提高了其市場佔有率。

從應用角度來看，到2023 年，獲得性凝血因子缺乏症領域佔據了近一半的市場佔有率。為普遍。這種較高的發病率推動了臨床環境中對 PCC 的需求，在這些環境中，及時治療至關重要，特別是在手術或創傷病例中。 2023 年，北美成為 PCC 市場的領先地區，收入達 7.883 億美元，預計到 2032 年將達到 17 億美元。。此外，美國和加拿大先進的醫療基礎設施支援 PCC 治療的有效使用和監測，確保患者得到及時、有效率的照護。

市場範圍
開始年份	2023年
預測年份	2024-2032
起始值	21億美元
預測值	47 億美元
複合年成長率	9.4%

這種不斷成長的市場格局凸顯了 PCC 在治療凝血障礙和改善患者治療效果方面的重要性。

產業生態系統分析
產業影響力
- 成長動力
  - 凝血障礙的發生率增加
  - 對血漿相關療法的需求不斷成長
  - 技術創新
  - 研究與開發的進步
- 產業陷阱與挑戰
  - 來自替代品的激烈競爭
成長潛力分析
監管環境
技術景觀
報銷場景
定價分析
- 按地區
- 依產品
未來市場趨勢
專利分析
利潤率分析
管道分析
臨床試驗情況
差距分析
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按產品類型，2021 - 2032

主要趨勢
4因素PCC
三因素PCC

第 6 章：市場估計與預測：按應用分類，2021 - 2032

主要趨勢
後天性凝血因子缺乏症
先天性凝血因子缺乏症
其他應用

第 7 章：市場估計與預測：按最終用途，2021 - 2032 年

主要趨勢
醫院
門診手術中心
其他最終用戶

第 8 章：市場估計與預測：按地區分類，2021 - 2032 年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 荷蘭
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國

第 9 章：公司簡介

CSL
Baxter
Emergent BioSolutions
Grifols Biologicals
Intas Pharmaceuticals
Kedrion Biopharma
LFB Group
Octapharma
Pfizer
Prothya Biosolutions
Takeda Pharmaceuticals

簡介目錄

Product Code: 11940

The Global Prothrombin Complex Concentrate Market was valued at USD 2.1 billion in 2023 and is projected to grow at 9.4% CAGR from 2024 to 2032. This growth is primarily fueled by the rising prevalence of coagulation disorders and the increasing demand for plasma-derived therapies. The surge in coagulation disorders significantly contributes to the expansion of the PCC market worldwide. As conditions such as bleeding disorders and acquired coagulation disorders become more common, the need for effective and rapid treatment options like PCC has intensified. Factors such as vitamin K deficiency, liver diseases, and the widespread use of anticoagulant medications have further emphasized the importance of PCC, especially in emergency situations where quick intervention is essential.

The market is categorized by product type into 4-factor PCC and 3-factor PCC. In 2023, the 4-factor PCC segment led the market, generating approximately USD 1.2 billion. This product is often preferred in critical care settings due to its rapid onset of action and versatility in treating various conditions, including the reversal of direct oral anticoagulants. The strong endorsement of 4-factor PCC by clinical guidelines from various health organizations reinforces its position in coagulation-related treatments, further enhancing its market share.

From an application perspective, the segment for acquired coagulation factor deficiency captured nearly half of the market share in 2023. This type of disorder, often linked to conditions such as vitamin K deficiency or the effects of anticoagulant therapies, is more prevalent than congenital disorders. This higher incidence drives the demand for PCC in clinical settings where prompt treatment is essential, particularly during surgeries or trauma cases. North America emerged as the leading region in the PCC market in 2023, with revenues amounting to USD 788.3 million and expectations to reach USD 1.7 billion by 2032. The increasing prevalence of coagulation disorders, particularly in older populations, is a significant driver of PCC demand. Moreover, the advanced healthcare infrastructure in the U.S. and Canada supports the effective use and monitoring of PCC treatments, ensuring patients receive timely and efficient care.

Market Scope
Start Year	2023
Forecast Year	2024-2032
Start Value	$2.1 Billion
Forecast Value	$4.7 Billion
CAGR	9.4%

This growing market landscape highlights the importance of PCC in managing coagulation disorders and enhancing patient outcomes.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increased incidence of coagulation disorders
  - 3.2.1.2 Growing demand for plasma-related therapies
  - 3.2.1.3 Technological innovations
  - 3.2.1.4 Advancements in research and development
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Intense competition from alternatives
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Reimbursement scenario
3.7 Pricing analysis
- 3.7.1 By region
- 3.7.2 By product
3.8 Future market trends
3.9 Patent analysis
3.10 Profit margin analysis
3.11 Pipeline analysis
3.12 Clinical trial landscape
3.13 Gap analysis
3.14 Porter's analysis
3.15 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 4-factor PCC
5.3 3-factor PCC

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Acquired coagulation factor deficiency
6.3 Congenital coagulation factor deficiency
6.4 Other applications

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospitals
7.3 Ambulatory surgical centers
7.4 Other end users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Spain
- 8.3.6 Netherlands
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE